HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

Mantle cell lymphoma (MCL) is a highly aggressive and heterogeneous B-cell lymphoma. Though Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown great efficacy as a single agent for MCL treatment, the real-world use of ibrutinib is still subject to limitations. Our previous study has shown t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ziwen, Wang, Zhixin, Tu, Zhigang, Liu, Hanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204102/
https://www.ncbi.nlm.nih.gov/pubmed/35721157
http://dx.doi.org/10.3389/fphar.2022.864194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204102/
https://www.ncbi.nlm.nih.gov/pubmed/35721157
http://dx.doi.org/10.3389/fphar.2022.864194

Ejemplares similares